Nerve Recovery Protocol

Overview

Nerve injury — whether peripheral (carpal tunnel, sciatic nerve compression, traumatic neuropathy) or central (stroke, traumatic brain injury, neurodegenerative processes) — presents unique healing challenges compared to other tissue types. Neurons have limited regenerative capacity, particularly in the central nervous system (CNS), and the timeline for nerve recovery is measured in months rather than weeks.

Peptide-based approaches to nerve recovery focus on two complementary strategies: neuroprotection (preserving existing neuronal function and preventing secondary damage) and neuroregeneration (supporting axonal regrowth, remyelination, and synaptogenesis). This protocol combines three peptides that have been studied for their neurotrophic and neuroprotective properties across preclinical and, in some cases, clinical research.

BPC-157 has demonstrated neuroprotective effects in multiple preclinical models, including peripheral nerve crush injuries, where it appears to accelerate axonal regeneration and improve functional recovery. Cerebrolysin is a porcine brain-derived peptide preparation that contains neurotrophic factors and has been studied in clinical trials for stroke and traumatic brain injury. Semax is a synthetic analog of adrenocorticotropic hormone (ACTH) fragment 4-10 that has been investigated for its neurotrophic and cognitive-enhancing properties, primarily in Russian clinical research.

Compounds Involved

Protocol Structure

Nerve recovery protocols tend to be longer in duration than musculoskeletal healing protocols, reflecting the slower pace of neuronal repair. This protocol is structured for a 12–16 week course.

Phase 1: Neuroprotection (Weeks 1–4)

The initial phase prioritizes protecting existing neuronal tissue and establishing a neurotrophic environment that supports subsequent regeneration.

BPC-157:

• Dose: 250–500 mcg per day
• Frequency: Twice daily (split dosing — e.g., 250 mcg morning, 250 mcg evening)
• Injection site: Subcutaneous, near the site of peripheral nerve injury when applicable. For central nervous system concerns, standard abdominal SubQ administration is used
• Rationale: BPC-157's effects on nitric oxide systems and growth factor expression begin early. Establishing tissue levels during the acute or subacute phase may limit secondary neuronal damage

Semax:

• Dose: 200–600 mcg per day
• Frequency: 2–3 times daily, divided doses
• Route: Intranasal spray (each spray typically delivers 50–100 mcg depending on the preparation)
• Timing: Morning and midday administration is common. Some users avoid evening dosing due to potential mild stimulatory effects
• Rationale: Semax's ability to upregulate brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF) expression supports the neuroprotective environment during the early recovery phase

Phase 2: Neuroregeneration Support (Weeks 5–12)

The second phase introduces Cerebrolysin (where available and administered under clinical supervision) while continuing BPC-157 and Semax to support active nerve regeneration.

Cerebrolysin:

• Dose: 5–10 mL per day (clinical dosing). Specific dose protocols vary based on the nature and severity of the neurological injury
• Frequency: Once daily for 10–21 consecutive days per treatment cycle. Multiple cycles may be administered with 2–4 week rest periods between them
• Route: Intramuscular injection for lower doses; intravenous infusion for higher doses. This compound requires clinical administration
• Important: Cerebrolysin is a prescription medication in many countries and is not available as a research peptide in all jurisdictions. Its inclusion in this protocol reflects its clinical research profile. See Peptide Regulation Worldwide for jurisdictional considerations

Continue BPC-157:

• Dose: 250 mcg per day
• Frequency: Once daily (reduced from twice daily)
• Continue through: Week 12–16

Continue Semax:

• Dose: 200–400 mcg per day
• Frequency: 2 times daily
• Continue through: Week 12–16, with optional 1-week breaks every 4 weeks

Phase 3: Maintenance and Recovery Assessment (Weeks 13–16)

The final phase reduces compound frequency while maintaining neurotrophic support as functional recovery is assessed.

BPC-157: 200 mcg per day, once daily Semax: 200 mcg per day, once daily (morning) Cerebrolysin: Additional cycles if clinically indicated

Phase Summary Table

Peripheral vs. Central Nerve Injury Considerations

The approach differs depending on the injury location:

Peripheral Nerve Injuries

• Examples: Carpal tunnel syndrome, peripheral neuropathy, nerve entrapment, traumatic nerve transection
• BPC-157 injection site: As close to the injured nerve as anatomically practical via subcutaneous injection
• Prognosis: Peripheral nerves have greater regenerative capacity than central nerves, with axonal regrowth rates of approximately 1 mm per day after initial delay
• Physical therapy: Active and passive range-of-motion exercises, nerve gliding exercises, and progressive strengthening are essential complements

Central Nervous System Injuries

• Examples: Stroke recovery, traumatic brain injury, spinal cord injury
• BPC-157 injection site: Standard abdominal subcutaneous injection (systemic delivery)
• Cerebrolysin: May be more relevant for CNS injuries given its clinical research in stroke and TBI populations
• Prognosis: CNS regeneration is more limited, and the focus often shifts toward neuroplasticity — the brain's ability to reorganize existing neural pathways to compensate for damaged areas
• Rehabilitation: Cognitive rehabilitation, speech therapy, and occupational therapy as indicated

Important Considerations

• Clinical supervision is strongly recommended: Nerve injuries, particularly CNS injuries, require professional diagnosis and monitoring. Peptide use in this context should be discussed with a neurologist or qualified healthcare provider.
• Cerebrolysin requires medical administration: This compound is not suitable for self-administration. It requires proper clinical oversight, particularly when given intravenously.
• Semax availability: Semax is approved as a prescription medication in Russia and several CIS countries but is not FDA-approved in the United States. Availability and legal status vary by jurisdiction.
• Patience is essential: Nerve regeneration is slow. Peripheral nerve recovery may take 3–12 months depending on injury severity and distance to the target tissue. CNS recovery timelines are even more variable.
• Electrophysiology monitoring: Nerve conduction studies (NCS) and electromyography (EMG) provide objective measurements of nerve function and recovery progress. Baseline and periodic testing can document improvement.
• Avoid alcohol and neurotoxins: Substances that impair neuronal function or regeneration should be minimized during a nerve recovery protocol.
• Sleep optimization: Neurotrophic factor expression, including BDNF and NGF, is closely linked to sleep quality. See the Sleep Optimization Protocol for relevant strategies.

Disclaimer

This article is for educational and informational purposes only. It does not constitute medical advice, and no therapeutic claims are made. Peptide research is ongoing, and individual outcomes may vary. Consult a qualified healthcare professional before beginning any peptide protocol. All compounds discussed are intended for research purposes.